Weight Loss
Menopause
menu-close
WHAT WE TREAT
Weight loss
icon
Menopause
icon
ACCOUNT
Log in
icon
OVERVIEW
Weight loss overview
icon
TREATMENTS
Explore all options
Explore all options
icon
Mounjaro
Mounjaro
Lose up to 23% body weight
icon
Wegovy
Wegovy
Lose up to 21% body weight
icon
Saxenda
Saxenda
Lose up to 10% body weight
icon
Orlos
Orlos
Lose up to 8% body weight
icon
PROGRAMME
How it works
How it works
icon
Coaching
Coaching
icon
App
App
icon
ABOUT
Results
icon
Experts
icon
RESOURCES
Guides & tips
icon
ACCOUNT
Log in
icon
GET IN TOUCH
020 3912 9885
Mon-Fri 9:00-17:30
icon
OUR CLINIC
Menopause overview
icon
Pricing
icon
Clinicians
icon
TREATMENT PLANS
Hormone replacement therapy
icon
Testosterone treatment
icon
Cognitive behavioural therapy
icon
Vaginal treatments
icon
BLOOD TESTS
Women's midlife (MOT) blood test
icon
Monitor HRT blood test
icon
Start testosterone blood test
icon
WHAT WE TREAT
Skincare
New
icon
Perimenopause
icon
Menopause
icon
Sexual health
icon
Weight management
icon
LEARN
Guides
icon
Treatments
icon
ACCOUNT
Log in
icon
SUPPORT
FAQ
icon
Home/Guides & Tips/Weight loss/

Is Retatrutide available on the NHS?

Is Retatrutide available on the NHS?

Wondering if retatrutide is available on the NHS, and how to get it? Here’s everything you need to know about the new weight loss medication that’s generating a lot of buzz.

clinician image

Medically reviewed by

Dr Earim Chaudry (MBBS), Chief Medical Officer

iconPublished 31st October 2025
Research-Based Guide
Table of contents
  • Why retatrutide isn’t yet appr...
  • Who will likely qualify for re...
  • When could retatrutide become ...
  • Private alternatives to retatr...

Retatrutide is a new weight-loss drug being developed by Eli Lilly, the company behind Mounjaro. Early clinical trials suggest it could deliver an average weight loss of around 24.2% after 48 weeks—greater than any other obesity treatment tested to date.

But retatutrutide hasn’t been approved yet. That means a doctor can’t prescribe it to you and you can’t get it on the NHS at the moment.

Why retatrutide isn’t yet approved for NHS prescription

Retatrutide isn’t yet approved on the NHS because it’s still in clinical trials. This means that researchers are testing how safe and effective the drug is, and how it compares to other weight loss treatments already out there.

Retatrutide is currently in phase 3 clinical trials. A phase 2 study found that retatrutide has a greater impact on weight loss than Mounjaro and Wegovy, both of which are currently approved for weight loss on the NHS in the UK.

Learn more about retatrutide’s side effects, early study results, and how it’s different from other GLP-1s before deciding if it could be the right treatment for you.

Don't wait to hit your health goals
Retatrutide isn’t available yet, but Wegovy and Mounjaro are already helping people lose weight. Start your journey today with proven treatments and support that sticks.
icon
Science backed programme
icon
Personalised support
icon
Trusted by 100k customers across the UK

Who will likely qualify for retatrutide on the NHS?

As retatrutide isn’t available on prescription on the NHS (or approved for public use yet), we don’t know who will likely qualify for one.

Current guidelines for Mounjaro or Wegovy NHS prescriptions prioritise patients who have been diagnosed with severe obesity. This ensures the people who need it most will have first access to treatment.

We can use existing checklists to give us an idea of who could qualify for retatrutide on the NHS.

To get a Mounjaro (tirzepatide) NHS prescription, you must:

  • Have a consultation with your GP or a specialist weight management service
  • Have a BMI of 40 or more (or 37.5 for some ethnicities)
  • AND have four or more weight-related conditions (such as type 2 diabetes, high blood pressure, heart disease, high cholesterol, sleep apnoea)
  • Agree to eat a balanced, reduced-calorie diet and do regular physical activity alongside it

To get a Wegovy (semaglutide) prescription on the NHS, you must:

  • Have a consultation with a specialist weight management service recommended by your GP
  • Have health problems due to your weight
  • Have a BMI of 35 or more (or 32.5 for some ethnicities)
  • Have a BMI of 30 to 34.9 (or 27.5 to 32.4 for some ethnicities) AND you meet other criteria to be treated by a specialist weight management service

If you’re not sure if you qualify for a Wegovy or Mounjaro NHS prescription, speak to your GP.

When could retatrutide become available on the NHS?

We don’t know when retatrutide will be available on the NHS. If it passes phase 3 clinical trials, it could be available in late 2026 at the earliest.

Private alternatives to retatrutide that are available in the UK now

Retatrutide is not available on the NHS or privately as it’s still being tested in clinical trials.

If retatrutide does get approved, it will likely become available via Voy’s weight loss programmes. In the meantime, we’ll keep sharing everything we know so far about retatrutide.

Want to start your weight loss journey now? Access effective weight loss medications like Wegovy, Mounjaro, and orlistat through Voy. Just take our quiz to find out if you’re eligible.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
FAQ

Retatrutide on the NHS: FAQ

Dr Earim Chaudry, MBBS
DisclaimerAt Voy, we ensure that everything you read in our blog is medically reviewed and approved. However, the information provided is not meant to replace professional medical advice, diagnosis, or treatment. It should not be relied upon for specific medical advice.
References
icon¹

“Clinical Trials.” NHSscribble-underline, Oct. 2017, www.nhs.uk/tests-and-treatments/clinical-trials/. Accessed 27 Oct. 2025.

icon²

“Eli Lilly Infiltrates Anti-Obesity Market as Phase III Trial for Retatrutide Begins.” Clinical Trials Arenascribble-underline, 31 Aug. 2023, www.clinicaltrialsarena.com/analyst-comment/eli-lilly-infiltrates-anti-obesity-market-phase-iii-trial-retatrutide/. Accessed 27 Oct. 2025.

icon³

Jastreboff, Ania M., et al. "Triple–hormone-receptor Agonist Retatrutide for Obesity—a Phase 2 Trial." New England Journal of Medicinescribble-underline 389.6 (2023): 514-526.

icon⁴

“Medication Guide MOUNJARO®.” Dailymedscribble-underline, National Library of Medicine, dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0. Accessed 27 Oct. 2025.

icon⁵

“Weight Management Injections.” NHSscribble-underline, www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/. Accessed 27 Oct. 2025.

Take the first step towards weight loss that lasts.

card-image
Weight Loss
Retatrutide results: Real data vs online hype
Doctors can’t prescribe retatrutide just yet. But here’s what we do know about weight loss results from clinical trials.
card-image
Weight Loss
BMI for weight-loss injections
Curious whether your body mass index (BMI) makes you eligible for GLP-1 weight-loss injections like Wegovy or Mounjaro? You’re not alone. It’s one of the most frequently asked questions about these treatments.
card-image
Weight Loss
Retatrutide vs Wegovy
Here’s what we know so far about how retatrutide compares to Wegovy.
Have a question?
phone icon
020 3912 9885Monday - Friday 9am - 5pm
support icon
help@joinvoy.comWe aim to reply in 24hrs
email icon
press@joinvoy.comPress & media inquiries
Our services are not intended for use in a medical emergency. If you need urgent medical attention, please call 111 or 999.

Programme

  • How it works
  • Treatments
  • Coaching
  • The Voy App

Voy

  • Medical experts
  • Results

Legal

  • Privacy policy
  • Terms & Conditions
  • Terms of Sale
  • Complaints

Get help

  • Help Centre (FAQ)
facebooktwitterinstagram
Copyright 2025 Voy. All rights reserved.
Pharmacies: Manual PharmacySuperintendent Pharmacist: Vinisha KandaGPhC Registration: 2203475
registered pharmacycqc ratingcpd member